NASDAQ:PTCT - PTC Therapeutics Stock Price, Forecast & News

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

PTC Therapeutics, Inc. (NASDAQ:PTCT) released its quarterly earnings data on Tuesday, October, 29th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.91) by $0.15. The biopharmaceutical company had revenue of $71.40 million for the quarter, compared to analyst estimates of $72.03 million. PTC Therapeutics had a negative return on equity of 31.92% and a negative net margin of 74.86%. The firm's revenue for the quarter was up 33.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.06) EPS. View PTC Therapeutics' Earnings History.

PTC Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for PTC Therapeutics.

PTC Therapeutics issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $306-306 million, compared to the consensus revenue estimate of $302.78 million.

10 equities research analysts have issued 12 month target prices for PTC Therapeutics' stock. Their forecasts range from $43.00 to $78.00. On average, they anticipate PTC Therapeutics' stock price to reach $56.50 in the next year. This suggests a possible upside of 5.6% from the stock's current price. View Analyst Price Targets for PTC Therapeutics.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PTC Therapeutics.

Media stories about PTCT stock have been trending very negative on Wednesday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PTC Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for PTC Therapeutics.

Some companies that are related to PTC Therapeutics include Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Horizon Therapeutics (HZNP) and Amarin (AMRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Regulus Therapeutics (RGLS), Cisco Systems (CSCO), Aduro BioTech (ADRO) and Gilead Sciences (GILD).

PTC Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.98%) and Assenagon Asset Management S.A. (0.17%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.

PTCT stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A.. Company insiders that have sold PTC Therapeutics company stock in the last year include Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Neil Gregory Almstead and Stuart Walter Peltz. View Insider Buying and Selling for PTC Therapeutics.

PTCT stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for PTC Therapeutics.

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PTCT stock can currently be purchased for approximately $53.51.

PTC Therapeutics has a market capitalization of $3.30 billion and generates $264.73 million in revenue each year. The biopharmaceutical company earns $-128,080,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. PTC Therapeutics employs 511 workers across the globe.View Additional Information About PTC Therapeutics.

The official website for PTC Therapeutics is http://www.ptcbio.com/.

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]